Corporate GovernanceApr 30, 2026, 06:12 AM
SGMO Discloses 2025 Executive Comp; Salary Hikes, Bonuses Deferred
AI Summary
Sangamo Therapeutics, Inc. filed an amended 10-K/A to include previously omitted information for Part III, Items 10-14, which covers directors, executive officers, corporate governance, and executive compensation. The company disclosed that 2025 executive salary increases, including a 4% raise for the CEO to $745,020, and cash incentive bonuses were approved but deferred due to ongoing financial constraints and the need to conserve capital. Notably, CEO Alexander D. Macrae voluntarily waived his 2025 cash bonus of $178,805.
Key Highlights
- SGMO filed 10-K/A to include omitted Part III info (Items 10-14) due to delayed proxy statement.
- 2025 executive salary increases, including CEO's +4% to $745,020, deferred due to financial constraints.
- 2025 cash incentive bonuses, like CDO's $79,834, earned but deferred until funding secured.
- CEO Alexander D. Macrae voluntarily waived his 2025 cash bonus of $178,805.
- Company achieved 40% of its 2025 corporate objectives for incentive compensation.
- Audit Committee comprises Robert F. Carey (Chair), John H. Markels, and James R. Meyers.
- Robert F. Carey is designated as an "audit committee financial expert" by the Board.
Price Impact
More from SGMO